Updating results

428 results

Sort: Relevance | Date

Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]

In development [GID-TA10607] Expected publication date: TBC

Technology appraisal guidance In development

Omburtamab with radioactive iodine (131I) for treating relapsed neuroblastoma [ID1664]

In development [GID-TA10608] Expected publication date: TBC

Technology appraisal guidance In development

Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596

In development [GID-TA10497] Expected publication date: 11 November 2020

Technology appraisal guidance In development

Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis [ID1521]

In development [GID-TA10471] Expected publication date: 04 March 2020

Technology appraisal guidance In development

Pembrolizumab for untreated metastatic or unresectable recurrent squamous cell head and neck cancer [ID1140]

In development [GID-TA10181] Expected publication date: TBC

Technology appraisal guidance In development

Gilteritinib for treating relapsed or refractory acute myeloid leukaemia [ID1484]

In development [GID-TA10460] Expected publication date: TBC

Technology appraisal guidance In development

Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma [ID2708]

In development [GID-TA10588] Expected publication date: 24 March 2021

Technology appraisal guidance In development

Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID1504]

In development [GID-TA10400] Expected publication date: TBC

Technology appraisal guidance In development

Liraglutide for managing overweight and obesity [ID740]

In development [GID-TA10388] Expected publication date: 13 May 2020

Technology appraisal guidance In development

Avelumab for treating metastatic Merkel cell carcinoma (CDF Review of TA517) ID1617

In development [GID-TA10545] Expected publication date: 19 September 2020

Technology appraisal guidance In development

Brentuximab vedotin for untreated CD30-positive peripheral T-cell lymphoma ID1586

In development [GID-TA10514] Expected publication date: 12 August 2020

Technology appraisal guidance In development

Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

In development [GID-TA10527] Expected publication date: TBC

Technology appraisal guidance In development

Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]

In development [GID-TA10589] Expected publication date: TBC

Technology appraisal guidance In development

MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]

In development [GID-TA10573] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) ID1585

In development [GID-TA10538] Expected publication date: 12 August 2020

Technology appraisal guidance In development

Nivolumab with cisplatin and fluorouracil for untreated advanced oesophageal squamous cell carcinoma [ID2712]

In development [GID-TA10572] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer ID1429

In development [GID-TA10512] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab-relatlimab for untreated advanced or metastatic melanoma [ID1688]

In development [GID-TA10581] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (CDF Review TA600) ID1683

In development [GID-TA10537] Expected publication date: 12 August 2020

Technology appraisal guidance In development

Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]

In development [GID-TA10583] Expected publication date: TBC

Technology appraisal guidance In development

Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]

In development [GID-TA10467] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab with tremelimumab for untreated unresectable hepatocellular carcinoma [ID2725]

In development [GID-TA10571] Expected publication date: 25 August 2021

Technology appraisal guidance In development

Atezolizumab with paclitaxel for untreated unresectable advanced triple-negative breast cancer [ID2705]

In development [GID-TA10570] Expected publication date: TBC

Technology appraisal guidance In development

Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after alectinib or ceritinib [ID2702]

In development [GID-TA10569] Expected publication date: TBC

Technology appraisal guidance In development

Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 3 therapies [ID2701]

In development [GID-TA10568] Expected publication date: TBC

Technology appraisal guidance In development

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [ID2697]

In development [GID-TA10582] Expected publication date: TBC

Technology appraisal guidance In development

Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 1 systemic therapy [ID1684]

In development [GID-TA10580] Expected publication date: TBC

Technology appraisal guidance In development

Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma [ID2709]

In development [GID-TA10579] Expected publication date: 21 April 0201

Technology appraisal guidance In development

Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin lymphoma [ID1685]

In development [GID-TA10578] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma [ID1629]

In development [GID-TA10576] Expected publication date: TBC

Technology appraisal guidance In development

Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

In development [GID-TA10575] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab in combination for untreated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID2700]

In development [GID-TA10574] Expected publication date: TBC

Technology appraisal guidance In development

Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

In development [GID-HST10004] Expected publication date: TBC

Highly specialised technologies guidance In development

Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

In development [GID-HST10007] Expected publication date: TBC

Highly specialised technologies guidance In development

Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer ID1413

In development [GID-TA10329] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer ID1357

In development [GID-TA10322] Expected publication date: TBC

Technology appraisal guidance In development

Moxetumomab pasudotox for hairy-cell leukaemia [ID1142]

In development [GID-TA10288] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

In development [GID-TA10295] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy ID1264

In development [GID-TA10365] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]

In development [GID-TA10164] Expected publication date: TBC

Technology appraisal guidance In development

Multiple sclerosis (primary-progressive) - fingolimod [ID62]

In development [GID-TAG221] Expected publication date: TBC

Technology appraisal guidance In development

Atrial fibrillation - ximelagatran [ID376]

In development [GID-TAG377] Expected publication date: TBC

Technology appraisal guidance In development

Juvenile idiopathic arthritis - adalimumab [ID385]

In development [GID-TAG400] Expected publication date: TBC

Technology appraisal guidance In development

Psoriatic arthritis (moderate to severe) - leflunomide [ID391]

In development [GID-TAG385] Expected publication date: TBC

Technology appraisal guidance In development

Clinically isolated syndrome - beta interferons and glatiramer acetate [ID109]

In development [GID-TAG415] Expected publication date: TBC

Technology appraisal guidance In development

Atrial fibrillation - idraparinux sodium [ID375]

In development [GID-TAG383] Expected publication date: TBC

Technology appraisal guidance In development

Dabrafenib with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer [ID929]

In development [GID-TA10121] Expected publication date: TBC

Technology appraisal guidance In development

Heart failure (acute decompensated) - nesiritide [ID384]

In development [GID-TAG376] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (first line treatment) - sunitinib (in combination with a taxane) [ID58]

In development [GID-TAG391] Expected publication date: TBC

Technology appraisal guidance In development

Diabetic retinopathy - ruboxistaurin [ID382]

In development [GID-TAG386] Expected publication date: TBC

Technology appraisal guidance In development